Background. It is well known that most neurodegenerative diseases are associated with microglia-mediated inflammation. Our previous research demonstrates that the CD40 signaling is critically ...

imperial.ac.uk Background Interferon gamma release assays (IGRAs) are the first new diagnostic tests for latent tuberculosis (TB) infection (LTBI) since the century-old tuberculin skin test (TST).

To examine the effect apigenin and luteolin had on microglial activation via CD40, we initially treated N9 microglia cells over a range of concentrations. Following FACS analysis, we found that ...

CD40 surface display was determined by FACS analysis and mRNA expression by reverse transcription-polymerase chain reaction. Secretion of cytokines was determined by ELISA. Nuclear factor κB (NFκB) ...

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL ... of TRAIL was not observed in NK cell–depleted mice or interferon-γ–deficient mice, the latter of which lacked TRAIL on ...

Our work has generated investment ideas in health care, consumer electronics, finance technologies, transportation, AI-based Oppenheimer raised the firm’s price target on Ligand (LGND ...

Researchers now offer a simplified method they call ProteinReDiff that uses artificial intelligence to speed the redesign of ligand-binding proteins. In biology, the binding of cellular proteins ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Background: Depressive disorders are highly prevalent among people with HIV (PWH) and are related to aberrant inflammation and immune responses. However, there is currently a lack of investigation ...

The gamma-delta neutral spread may be the best middle ground when searching for a way to exploit time decay while neutralizing the effect of price actions on your position's value. In this article ...

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and ...